- Previous Close
2.9000 - Open
2.8300 - Bid 2.8000 x --
- Ask 2.9000 x --
- Day's Range
2.8160 - 2.9000 - 52 Week Range
1.0630 - 7.7970 - Volume
432,516 - Avg. Volume
3,769,921 - Market Cap (intraday)
22.289M - Beta (5Y Monthly) 1.51
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0400 - Earnings Date Sep 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.17
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.
www.shieldtherapeutics.com73
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: STX.L
View MorePerformance Overview: STX.L
Trailing total returns as of 11/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: STX.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: STX.L
View MoreValuation Measures
Market Cap
22.68M
Enterprise Value
32.15M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.29
Price/Book (mrq)
52.54
Enterprise Value/Revenue
1.88
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-168.42%
Return on Assets (ttm)
-47.85%
Return on Equity (ttm)
-261.67%
Revenue (ttm)
21.47M
Net Income Avi to Common (ttm)
-36.17M
Diluted EPS (ttm)
-0.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
8.1M
Total Debt/Equity (mrq)
3,691.50%
Levered Free Cash Flow (ttm)
-12.1M